AP2008004379A0 - Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient - Google Patents

Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient

Info

Publication number
AP2008004379A0
AP2008004379A0 AP2008004379A AP2008004379A AP2008004379A0 AP 2008004379 A0 AP2008004379 A0 AP 2008004379A0 AP 2008004379 A AP2008004379 A AP 2008004379A AP 2008004379 A AP2008004379 A AP 2008004379A AP 2008004379 A0 AP2008004379 A0 AP 2008004379A0
Authority
AP
ARIPO
Prior art keywords
agomelatine
treatment
sleep disorder
medicaments intended
depressed patient
Prior art date
Application number
AP2008004379A
Other languages
English (en)
Inventor
Bruno Delalleau
Original Assignee
Lea Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36200255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2008004379(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lea Laboratoires Servier filed Critical Lea Laboratoires Servier
Publication of AP2008004379A0 publication Critical patent/AP2008004379A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AP2008004379A 2005-09-09 2006-09-08 Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient AP2008004379A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0509207A FR2890562B1 (fr) 2005-09-09 2005-09-09 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
PCT/FR2006/002068 WO2007028905A1 (fr) 2005-09-09 2006-09-08 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime

Publications (1)

Publication Number Publication Date
AP2008004379A0 true AP2008004379A0 (en) 2008-04-30

Family

ID=36200255

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004379A AP2008004379A0 (en) 2005-09-09 2006-09-08 Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient

Country Status (26)

Country Link
US (1) US20070060655A1 (es)
EP (2) EP1762237A1 (es)
JP (1) JP2007077148A (es)
KR (2) KR20070029608A (es)
CN (1) CN1927193B (es)
AP (1) AP2008004379A0 (es)
AR (1) AR056063A1 (es)
AU (1) AU2006209372A1 (es)
BR (1) BRPI0603762A (es)
CA (1) CA2558762A1 (es)
EA (1) EA014288B1 (es)
FR (1) FR2890562B1 (es)
GE (1) GEP20094602B (es)
GT (1) GT200600409A (es)
HK (1) HK1100481A1 (es)
MA (1) MA28506B1 (es)
MX (1) MXPA06010233A (es)
NO (1) NO20064050L (es)
NZ (1) NZ549726A (es)
PE (1) PE20070333A1 (es)
SG (1) SG146451A1 (es)
TW (1) TW200800148A (es)
UA (1) UA81573C2 (es)
UY (1) UY29777A1 (es)
WO (1) WO2007028905A1 (es)
ZA (1) ZA200607531B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918370B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2918372B1 (fr) * 2007-07-02 2009-08-28 Servier Lab Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN102190595A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀溴化氢水合物及其制备方法
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
CN101991559B (zh) * 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
WO2013119605A1 (en) * 2012-02-07 2013-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Promoting sleep using at1 receptor blockers
CN102552211B (zh) * 2012-02-16 2013-07-17 福建广生堂药业股份有限公司 一种阿戈美拉汀的制剂组合物及其制备方法
PT2810656T (pt) 2013-06-06 2017-11-13 Zentiva As Formulações de agomelatina compreendendo agomelatina na forma de cocristais
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression
CN103690499B (zh) * 2013-12-23 2015-05-06 天津泰普药品科技发展有限公司 一种稳定的晶i型阿戈美拉汀片剂及其制备方法
CN103655499B (zh) * 2013-12-23 2015-07-22 天津泰普药品科技发展有限公司 一种稳定的晶x型阿戈美拉汀片剂及其制备方法
CN104523639B (zh) * 2014-12-11 2017-03-22 扬子江药业集团四川海蓉药业有限公司 一种阿戈美拉汀片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7645905B2 (en) * 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7635721B2 (en) * 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
FR2890562A1 (fr) 2007-03-16
KR20070029608A (ko) 2007-03-14
NZ549726A (en) 2008-03-28
SG146451A1 (en) 2008-10-30
KR20080103043A (ko) 2008-11-26
EP2295050A1 (fr) 2011-03-16
GEP20094602B (en) 2009-02-10
GT200600409A (es) 2007-04-30
WO2007028905A1 (fr) 2007-03-15
AU2006209372A1 (en) 2007-03-29
JP2007077148A (ja) 2007-03-29
FR2890562B1 (fr) 2012-10-12
NO20064050L (no) 2007-03-12
EA014288B1 (ru) 2010-10-29
UA81573C2 (en) 2008-01-10
PE20070333A1 (es) 2007-06-02
CN1927193A (zh) 2007-03-14
MA28506B1 (fr) 2007-04-03
TW200800148A (en) 2008-01-01
HK1100481A1 (en) 2007-09-21
BRPI0603762A (pt) 2007-05-15
CA2558762A1 (fr) 2007-03-09
CN1927193B (zh) 2011-01-05
AR056063A1 (es) 2007-09-19
EA200601449A1 (ru) 2007-04-27
UY29777A1 (es) 2006-10-31
MXPA06010233A (es) 2007-03-08
EP1762237A1 (fr) 2007-03-14
US20070060655A1 (en) 2007-03-15
ZA200607531B (en) 2008-05-28

Similar Documents

Publication Publication Date Title
AP2008004379A0 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IL186662A (en) Use of bis (thiohydrazide amide) to prepare a drug for the treatment of human cancer
PL3542869T3 (pl) Jednorazowy monitor snu i oddechu
HK1170429A1 (en) Alpha aminoamide derivatives useful in the treatment of cognitive disorders
IL178815A0 (en) The treatment of respiratory disease
AP2488A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
HRP20130622T1 (en) Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
IL178827A0 (en) Use of reboxetine for the treatment of pain
GB0410399D0 (en) The treatment of respiratory disease
GB0619816D0 (en) Novel interferon-alpha constructs for use in the treatment of cancer
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
IL198134A (en) A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses
TWI318115B (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
GB0602110D0 (en) Use of ultrasound in the diagnosis and treatment of multiple sclerosis
TWI370735B (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0512726D0 (en) Multiple sclerosis therapy and diagnosis
GB0509911D0 (en) Medical treatment aid for use in treating children
HK1125634A1 (en) Pharmaceutical for use in the treatment of ureterolithiasis
AU2005901429A0 (en) Medical Apparatus and the Treatment of Lymphoedema